Samyang Biopharmaceutical Corp. participated in "2018 Korean Medical Pharmacology Association Spring Conference” to present “The Cases of Change in Dosage Form of Lenalidomide” in April 2018.

The presentation was mainly about changes in dosage forms of Lenalidomide, which is originally a capsule, into a tablet––the nonclinical and bioequivalence studies have demonstrated equivalent results for the comparator with the original product.

Meanwhile, Samyang Biopharmaceutical Corp. acquired approval from South Korea’s Ministry of Food and Drug Safety for Lenalid® Tab, August 2017.